Sun Pharmaceutical Industries Ltd.
Price
Daily candles · NSEWhat the numbers say
- Good return on equity: 3-year ROE 15.7%.
- Comfortable leverage: debt-to-equity of 0.05.
- Sales compounded at 10.0% over 3 years.
- Profits convert to cash well (CFO/OP 0.75).
- Trades above its industry P/E (36.6 vs 25.9).
Generated automatically from reported financials. These are observations, not a recommendation to buy or sell.
- Sun Pharma gets nod to raise up to Rs 10,000 crore via NCDs
The Board of Directors of the Company at its meeting held on October 12, 2026, has, inter alia, considered and approved the same
- Sun Pharma planning to raise Rs 15,000 crore via NCDs
A meeting of the Board of Directors of the Company is scheduled to be held on October 12, 2026, inter alia, to consider and approve the same
- Sun Pharma inks pact with LIB Therapeutics for ‘lerodalcibep’
Sun Pharma has been granted rights to commercialize and manufacture lerodalcibep worldwide, excluding the United States and China
- Sun Pharmaceutical incorporates subsidiary in GIFT City
The new entity has been incorporated to operate as the Global Treasury Centre for the Sun Pharma Group
- Sun Pharma reports 27% rise in Q1 consolidated net profit
Consolidated total income of the company increased by 11.93% to Rs 16,023.50 crore for Q1FY27
- Sun Pharm gets nod to manufacture, market semaglutide in Brazil
The company plans to launch the product in the next few days in partnership with Hypera Pharma, a leading pharmaceutical company in Brazil
- Sun Pharma gets nod to manufacture, market generic semaglutide in South Africa
The company has secured approval from the South African Health Products Regulatory Authority
- Sun Pharma to acquire Innovcare Lifesciences
The deal is worth around Rs 271.2 crore
Company announcements as filed with the exchanges. Reproduced for information — not a view or a recommendation.
| Profit & Loss · ₹ crore | FY26 | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|---|
| Net Sales | 58,462 | 52,578 | 48,497 | 43,886 | 38,654 |
| Other income | 3,212 | 2,151 | 1,628 | 694 | 1,437 |
| Total Income | 61,674 | 54,729 | 50,125 | 44,579 | 40,092 |
| Expenditure | 41,971 | 37,492 | 35,748 | 32,298 | 28,773 |
| Operating Profit | 19,703 | 17,237 | 14,377 | 12,281 | 11,319 |
| Interest | 339 | 231 | 238 | 172 | 127 |
| Depreciation | 2,938 | 2,575 | 2,557 | 2,529 | 2,144 |
| Profit before tax | 15,119 | 13,752 | 11,088 | 9,408 | 4,481 |
| Tax | 3,554 | 2,772 | 1,439 | 848 | 1,076 |
| Net Profit | 11,565 | 10,980 | 9,648 | 8,561 | 3,406 |
| EPS (₹) | 47.80 | 45.60 | 39.90 | 35.30 | 13.60 |
| Net margin % | 19.8 | 20.9 | 19.9 | 19.5 | 8.8 |
Consolidated figures, as filed with the exchanges. Newest year first.
| Balance Sheet · ₹ crore | FY26 | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|---|
| Equity capital | 240 | 240 | 240 | 240 | 240 |
| Reserves | 83,330 | 71,978 | 63,427 | 55,755 | 47,771 |
| Net worth | 83,570 | 72,218 | 63,667 | 55,995 | 48,011 |
| Total sources | 85,785 | 73,714 | 68,344 | 60,806 | 52,567 |
| Net block | 32,822 | 22,586 | 23,248 | 24,065 | 22,665 |
| Capital work in progress | 3,052 | 6,644 | 5,354 | 4,973 | 1,287 |
| Investments | 25,907 | 19,494 | 17,904 | 17,675 | 15,776 |
| Inventory | 11,493 | 10,243 | 9,868 | 10,513 | 8,925 |
| Debtors | 15,510 | 13,046 | 11,249 | 11,439 | 10,485 |
| Cash & bank | 11,603 | 11,332 | 10,521 | 5,770 | 5,033 |
| Book value (₹) | 348.31 | 301.00 | 265.36 | 233.38 | 200.11 |
Consolidated figures, as filed with the exchanges. Newest year first.
| Cash Flow · ₹ crore | FY26 | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|---|
| From operations | 12,419 | 14,072 | 12,135 | 4,959 | 8,985 |
| From investing | -11,344 | -5,306 | -690 | -7,944 | -5,725 |
| From financing | -2,513 | -7,906 | -6,710 | 2,376 | -5,193 |
| Net change in cash | -1,437 | 860 | 4,735 | -608 | -1,934 |
| Free cash flow | 1,075 | 8,766 | 11,445 | -2,984 | 3,260 |
| Closing cash | 9,771 | 10,269 | 9,286 | 4,624 | 4,508 |
Consolidated figures, as filed with the exchanges. Newest year first.
| Ratios | FY26 | FY25 | FY24 | FY23 | FY22 |
|---|---|---|---|---|---|
| ROCE % | 19.1 | 19.9 | 17.6 | 17.2 | 9.3 |
| ROE % | 14.8 | 16.2 | 16.1 | 16.5 | 7.2 |
| PAT margin % | 19.8 | 20.9 | 19.9 | 19.5 | 5.1 |
| EBIT margin % | 26.4 | 26.6 | 23.4 | 21.8 | 6.9 |
| Debt / equity | 0.05 | 0.03 | 0.04 | 0.11 | 0.02 |
| Current ratio | 2.82 | 2.89 | 2.56 | 2.00 | 2.03 |
| Interest cover | 45.61 | 60.44 | 47.50 | 55.70 | 36.19 |
| Sales growth % | 11.2 | 8.4 | 10.5 | 13.5 | 15.4 |
| Dividend per share (₹) | 16.00 | 16.00 | 13.50 | 11.50 | 10.00 |
| Payout % | 33.4 | 35.1 | 33.8 | 32.6 | 73.3 |
Consolidated figures, as filed with the exchanges. Newest year first.
Frequently asked
Sun Pharmaceutical Industries Ltd. (SUNPHARMA) last traded at ₹1,748.00 on the NSE, down +0.57% on the session. Prices on this page are indicative and for information only.
Sun Pharmaceutical Industries Ltd. has traded between ₹1,583.70 and ₹2,046.90 over the last 52 weeks on the NSE.
Sun Pharmaceutical Industries Ltd. has a market capitalisation of about ₹4,19,398 crore.
Sun Pharmaceutical Industries Ltd. trades at a P/E of 36.6, against an industry P/E of 25.9.
Open a trading and Demat account with Labdhi — it is fully digital with paperless KYC — then place a buy order for SUNPHARMA from the Labdhi app or web platform.
Yes. You can invest in equities in a staggered manner through Labdhi. Speak to your Labdhi adviser about a plan suited to your goals and risk profile.
Who is actually trading it
Delivery against churn, the deals big enough to be reported, what the insiders did, and the benchmarks that hold Sun Pharmaceutical Industries Ltd..
Loading trading activity…
Exchange filings and end-of-day data, not a live feed. Bulk, block and insider records are published by the exchanges when a threshold is crossed, so they show reportable activity only. For information, not a recommendation to deal, and not a view on any person named above.
Disclosures. Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI, membership of BASL (in case of IAs) and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.
Prices and data on this page are indicative and for information only. Nothing here is investment advice or a recommendation to buy or sell any security. Investors should consider their own objectives, financial situation and risk profile, and may wish to seek independent advice, before investing.
Figures are as reported by the company; consolidated where available. Errors and omissions excepted.
L. F. C. Securities Pvt. Ltd. · Member BSE, NSE, MCX · SEBI Stock Broker INZ000170736 · CDSL IN-DP-281-2016 · AMFI ARN-78991 · Investment Adviser (Non-Individual) INA000011617 · Compliance Officer: Mr. Santosh Patil · santoshp@labdhi.in · 022-35006933 · Investor Grievances: investorgreve@labdhi.in